These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15726382)

  • 1. Chemotherapy in metastatic renal cell cancer.
    Lilleby W; Fosså SD
    World J Urol; 2005 Jul; 23(3):175-9. PubMed ID: 15726382
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
    Siebels M; Staehler M; Hegele A; Varga Z; Oberneder R; Doehn C; Heinzer H;
    Aktuelle Urol; 2010 Mar; 41(2):122-30. PubMed ID: 19937556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil].
    May M; Helke C; Bock M; Hoschke B
    Urologe A; 2004 Sep; 43(9):1111-9. PubMed ID: 15232686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy in metastatic renal cell carcinoma today? A systematic review.
    Buti S; Bersanelli M; Sikokis A; Maines F; Facchinetti F; Bria E; Ardizzoni A; Tortora G; Massari F
    Anticancer Drugs; 2013 Jul; 24(6):535-54. PubMed ID: 23552469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cancer: an outpatient multicenter trial.
    Vogelzang NJ; Lipton A; Figlin RA
    J Clin Oncol; 1993 Sep; 11(9):1809-16. PubMed ID: 8355047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunotherapy of metastatic renal cell carcinoma with interleukin-2, interferon-alpha2a and erythropoietin-beta].
    Schenck M; Börgermann C; Jäger T; vom Dorp F; Sperling H; Rübben H; Lümmen G
    Urologe A; 2007 May; 46(5):528-34. PubMed ID: 17356836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell checkpoint inhibitors in metastatic renal cell carcinoma.
    Grünwald V
    Curr Opin Urol; 2015 Sep; 25(5):411-5. PubMed ID: 26125506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in metastatic renal cell carcinoma.
    Rohrmann K; Staehler M; Haseke N; Bachmann A; Stief CG; Siebels M
    World J Urol; 2005 Jul; 23(3):196-201. PubMed ID: 15806434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
    Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
    J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
    J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prospects for combination therapy with capecitabine in the rapidly evolving treatment landscape of renal cell carcinoma.
    Bilen MA; Carlisle JW; Sonpavde G
    Expert Opin Investig Drugs; 2018 Feb; 27(2):163-170. PubMed ID: 29323560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
    Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
    Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted therapy in the treatment of metastatic renal cell cancer.
    Di Lorenzo G; Scagliarini S; Di Napoli M; Scognamiglio F; Rizzo M; Carteni' G
    Oncology; 2009; 77 Suppl 1():122-31. PubMed ID: 20130440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial.
    Rini BI; Bellmunt J; Clancy J; Wang K; Niethammer AG; Hariharan S; Escudier B
    J Clin Oncol; 2014 Mar; 32(8):752-9. PubMed ID: 24297945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapeutic strategies for renal cell carcinoma.
    Milowsky MI; Nanus DM
    Urol Clin North Am; 2003 Aug; 30(3):601-9, x. PubMed ID: 12953758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
    Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
    J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
    Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
    Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
    Guida M; Colucci G
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi149-52. PubMed ID: 17591810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer.
    Parton M; Gore M; Eisen T
    J Clin Oncol; 2006 Dec; 24(35):5584-92. PubMed ID: 17158544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.